Dudley Lamming

Dr. Dudley Lamming is Professor and Vice Chair for Biomedical Research in the Department of Medicine at the University of Wisconsin-Madison, where he also serves as co-Director of the Wisconsin Nathan Shock Center of Excellence in the Basic Biology of Aging. He is Director of the UW-Madison Comprehensive Diabetes Center Mouse Phenotyping and Surgery Core and holds a research appointment at the William S. Middleton Memorial Veterans Hospital. Dr. Lamming received his PhD in Experimental Pathology from Harvard University in 2008 after completing his thesis research in the laboratory of Dr. David Sinclair, and subsequently completed postdoctoral training at the Whitehead Institute for Biomedical Research. His research there helped establish that many of the deleterious side effects of rapamycin, a drug that extends lifespan by inhibiting the protein kinase mTORC1, were mediated by “off-target” inhibition of a second complex, mTORC2. This work helped reshape our understanding of how rapamycin acts in vivo and has informed subsequent efforts to develop mTOR-targeted interventions for aging and age-related disease. Dr. Lamming is the author of over 100 peer-reviewed papers and has received numerous honors, including the 2018 Nathan Shock New Investigator Award from the Gerontological Society of America. He is a Fellow of both the American Aging Association and the Gerontological Society of America, and served as President of the American Aging Association from 2023-2024. His NIH-supported laboratory at the University of Wisconsin-Madison studies how nutrients and dietary composition regulate the molecular pathways that control aging and age-related disease. His lab has a particular interest in how altering specific dietary amino acids and other macronutrients can promote healthy aging and extend lifespan, and be used to prevent or treat age-associated diseases, including diabetes and Alzheimer’s disease.